Genetic and interventional clinical studies with PCSK9 monoclonal antibodies have demonstrated that PCSK9 inhibition efficiently reduces plasma LDL cholesterol and represent an efficient and safe strategy to protect against cardiovascular diseases (reviewed in (3)). Here, PCSK9 is linked to cardiovascular disorder.